.svg){kind=small}
Jul-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Avexia has demonstrated a consistent performance in the Illinois market, particularly in the Capsules and Topical categories, where they have maintained a steady second and first position, respectively, over the past four months. However, while their rank in Concentrates improved slightly from 14th to 12th, it indicates a competitive landscape in this category. In Maryland, Avexia has also shown strong performance in Capsules and Topicals, holding the second and first positions, respectively. Interestingly, their rank in Concentrates fluctuated, ending on a positive note by moving up to 20th in July. This suggests potential growth opportunities in this category if trends continue favorably.
In New Jersey, Avexia's presence in the Capsules category emerged strongly from May onwards, maintaining a solid second position. However, their performance in the Concentrates category saw a decline, dropping from 6th in April to 13th in July, which could be a point of concern. Additionally, Avexia's absence from the top 30 in Capsules in April and Tincture & Sublingual in July indicates areas where the brand may need to strengthen its market presence. In Ohio, Avexia maintained a consistent presence in the Tincture & Sublingual and Topical categories, holding steady at 4th place, which showcases their stable market positioning. However, their late entry into the Concentrates category in July with a 23rd rank could signal initial challenges in penetrating this segment.
Competitive Landscape
In the competitive landscape of the Illinois cannabis capsules market, Avexia has consistently maintained its position as the second-ranked brand from April to July 2025. Despite facing strong competition from the leading brand, 1906, which has held the top rank throughout the same period, Avexia has demonstrated resilience in its sales performance. While 1906 continues to dominate with significantly higher sales figures, Avexia's steady rank suggests a loyal customer base and effective brand strategies. Meanwhile, Pure Essentials and Breez have consistently ranked third and fourth, respectively, indicating a stable competitive environment. Avexia's ability to maintain its rank amidst these competitors highlights its strong market presence and potential for growth in the Illinois capsules category.
Notable Products
In July 2025, Avexia's top-performing product was the CBD/THC 1:1 Harmony Pain Relief Balm, maintaining its number one rank for four consecutive months with a sales figure of 9,097 units. The CBD/THC 4:1 Relief Tablets held steady at the second position, consistently performing well since May 2025. The CBN/CBD/THC 1:1:1 Comfort Tablets remained in third place, showing a slight decline in sales compared to previous months. The CBD/THC 1:1 Harmony Micro-Dosed Tablets retained their fourth position, indicating stable demand. Lastly, the CBG/THC 1:1 Ascend Tablets continued to rank fifth, with a marginal decrease in sales from June to July 2025.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
